Table 4 Cost-effectiveness of bisphosphonates for real-world and ideal persistence alternatives
Alternatives | No-treatment | Real-world persistence | Ideal persistence | |
|---|---|---|---|---|
Costs (Discounted) | Average per patients | €3,402 | €3,110 | €2,833 |
Incremental | -- | -€293* | -€277** | |
Costs (Undiscounted) | Average per patients | 4,428 € | €3,979 | €3,529 |
Incremental | -- | -€449* | -€450** | |
Fractured women | Proportion | 0.671 | 0.600 | 0.491 |
Incremental | -- | -0.071† | -0.109†† | |
ICER | Discounted | -- | (Dominated) €4,110 | (Dominated) €2,535 |
Undiscounted | -- | (Dominated) €6,310 | (Dominated) €4,114 | |
Premature deaths | Proportion | 0.061 | 0.049 | 0.034 |
Incremental | -- | -0,012† | -0,015†† | |
ICER | Discounted | -- | (Dominated) €25,073 | (Dominated) €18,442 |
Undiscounted | -- | (Dominated) €38,489 | (Dominated) €29,932 |